Is NVO a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

2,275 people get NVO articles and Market Currents by email alert.

Get email alerts on NVO »

HEADLINES:

Pricing A Highly Probable Takeover Of MannKind
George Rho • Wed, May 22 • 59 Comments
Oramed Sweeps Past Worldwide Giants With The First Trial Of Orally Delivered Insulin
Sharon di Stefano • Sun, May 19 • 50 Comments
Why MannKind's Afrezza Will Succeed Where Pfizer Failed
Cory Renauer • Sat, May 18 • 30 Comments
Novo Nordisk A/S Management Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 2
Novo Nordisk A/S Management Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 1
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Wed, May 1 • 59 Comments
Novo Nordisk Unveils New U.S. Headquarters

PR Newswire (Apr 19, 2013)
Clean Superiority Sweep For Dulaglutide Could Reshape Diabetes Market
EP Vantage • Wed, Apr 17 • 1 Comment
The Seeking Alpha Experiment: Portfolio Introduction And 2013 Quarter 1 Review
Nicholas Ward • Fri, Apr 12 • 62 Comments
Top Notch Long-Term Dividend Growers
Howard Reisman • Tue, Apr 9 • 20 Comments
Prolor Biotech: Unlimited Upside?
Daniel Lauchheimer • Tue, Apr 9 • 12 Comments
A Clouded Future For Big Pharma's Blockbuster Diabetes Drugs
Psycho Analyst • Wed, Apr 3 • 6 Comments
Novo Nordisk: Buy This 10 Year 27.47% CAGR Stock After Its Recent 16.94% Pullback
Nicholas Ward • Mon, Apr 1 • 5 Comments
How Much Will FDA Action On Invokana Affect Johnson & Johnson's Revenue And Stock Price?
Bio Vantage • Thu, Mar 28 • 4 Comments
Painless Play To Fatten Up Your Portfolio: Buy Arena
Wall Street Artist • Mon, Mar 25 • 46 Comments
Dividend Contenders: 18 Increases Expected By The End Of May
David Fish • Mon, Mar 18 • 4 Comments
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Fri, Mar 15 • 69 Comments
Longer Lasting Drugs Make For Longer Lasting Profits
Daniel Lauchheimer • Thu, Mar 14 • 2 Comments
Cramer's Mad Money - Why I'm Bullish On Airlines (3/5/13)
SA Editor Miriam Metzinger • Wed, Mar 6
Buy Novo Nordisk And Ride This Upward Trend
Nicholas Ward • Tue, Mar 5 • 19 Comments

Can Anything Stop Novo Nordisk?
Stephen Simpson • Tue, Feb 5 • 17 Comments

Novo Nordisk: Buy This 10 Year 27.47% CAGR Stock After Its Recent 16.94% Pullback
Nicholas Ward • Mon, Apr 1 • 5 Comments
Buy Novo Nordisk And Ride This Upward Trend
Nicholas Ward • Tue, Mar 5 • 19 Comments
The FDA Throws Novo Nordisk Off Course
Stephen Simpson • Mon, Feb 11 • 6 Comments
Can Anything Stop Novo Nordisk?
Stephen Simpson • Tue, Feb 5 • 17 Comments
Novo Nordisk: Wait And Watch
Shankar N • Fri, Dec 28, 2012 • 3 Comments
Novo Nordisk A/S: Catching The Increasing Diabetes Trend
Nick Chiu • Mon, Nov 19, 2012 • 4 Comments
The Soaring Diabetes Rate In The United States And Where To Invest
Nick Chiu • Mon, Nov 19, 2012
Degludec And Liraglutide: 2 Drivers Of Novo Nordisk's Growth
Jon Crowley • Tue, Nov 13, 2012 • 1 Comment
This Top-Performing Stock Is Tackling One Of The World's Deadliest Diseases
StreetAuthority • Thu, Nov 1, 2012 • 1 Comment
Novo Nordisk: A Great Pharma Stock, But Wait For A Pullback
Matthew Dow • Mon, Oct 29, 2012 • 6 Comments
Novo Nordisk: Encouraging Pipeline News
Zacks Investment Research • Tue, Oct 23, 2012
Novo Nordisk Is Positioned To Profit Off Of Obesity Epidemic But Price May Be Rich
Power Hedge • Tue, Oct 9, 2012 • 1 Comment
Novo Nordisk: Buy A Peer-Beating Firm
QuandaryFX • Tue, Oct 2, 2012 • 6 Comments
Novo Nordisk Still A Top-Notch Healthcare Growth Story
Stephen Simpson • Mon, Aug 13, 2012 • 7 Comments
Novo Nordisk's Oral Insulin Effort May Bear Big Rewards
Derek Lowe • Thu, May 24, 2012 • 1 Comment
Novo Nordisk Finally Looks (Slightly) Mortal
Stephen Simpson • Fri, Apr 27, 2012 • 6 Comments
Novo Nordisk Shares Can Be A Play On 'Obesity Exposure'
TradingFloor • Mon, Apr 16, 2012 • 3 Comments
Does Novo Nordisk's Pipeline Justify Its Premium?
Jon Crowley • Thu, Apr 5, 2012 • 17 Comments
Novo Nordisk: Increasing Diabetes Rate Should Benefit This Danish Pharmaceutical
Power Hedge • Fri, Jan 13, 2012 • 1 Comment
My Favorite Drug Stock
Bill Gunderson • Wed, Dec 21, 2011 • 9 Comments

Pricing A Highly Probable Takeover Of MannKind
George Rho • Wed, May 22 • 59 Comments
Oramed Sweeps Past Worldwide Giants With The First Trial Of Orally Delivered Insulin
Sharon di Stefano • Sun, May 19 • 50 Comments
Why MannKind's Afrezza Will Succeed Where Pfizer Failed
Cory Renauer • Sat, May 18 • 30 Comments
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Wed, May 1 • 59 Comments
Clean Superiority Sweep For Dulaglutide Could Reshape Diabetes Market
EP Vantage • Wed, Apr 17 • 1 Comment
The Seeking Alpha Experiment: Portfolio Introduction And 2013 Quarter 1 Review
Nicholas Ward • Fri, Apr 12 • 62 Comments
Top Notch Long-Term Dividend Growers
Howard Reisman • Tue, Apr 9 • 20 Comments
Prolor Biotech: Unlimited Upside?
Daniel Lauchheimer • Tue, Apr 9 • 12 Comments
A Clouded Future For Big Pharma's Blockbuster Diabetes Drugs
Psycho Analyst • Wed, Apr 3 • 6 Comments
How Much Will FDA Action On Invokana Affect Johnson & Johnson's Revenue And Stock Price?
Bio Vantage • Thu, Mar 28 • 4 Comments
Painless Play To Fatten Up Your Portfolio: Buy Arena
Wall Street Artist • Mon, Mar 25 • 46 Comments
Dividend Contenders: 18 Increases Expected By The End Of May
David Fish • Mon, Mar 18 • 4 Comments
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Fri, Mar 15 • 69 Comments
Longer Lasting Drugs Make For Longer Lasting Profits
Daniel Lauchheimer • Thu, Mar 14 • 2 Comments
Cramer's Mad Money - Why I'm Bullish On Airlines (3/5/13)
SA Editor Miriam Metzinger • Wed, Mar 6
4 Drug Delivery Companies That Deliver For Investors
Ryan's View • Wed, Feb 27
Biopharmaceutical Companies Developing Insulin Pills May Bring High Profits
Glen S. Woods • Thu, Feb 21 • 6 Comments
AbbVie: Cash Out, Hold Or Reinvest?
James Shell • Wed, Feb 20 • 3 Comments
Too Many Biotechnology Bargains: Which Is The Best Bet For 2013?
Timing Best Buy • Wed, Feb 20 • 5 Comments
If Investors Won't Buy Shire, Big Pharma Should
Stephen Simpson • Wed, Feb 20

Novo Nordisk A/S Management Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 2
Novo Nordisk A/S Management Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 1
Novo Nordisk's Management Hosts Region China Conference (Transcript)
Mon, Mar 4
Novo Nordisk A/S - Special Call
Mon, Feb 11
Novo Nordisk's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Jan 31 • 1 Comment
Novo Nordisk's CEO Discusses Q3 2012 Results - Earnings Call Transcript
Wed, Oct 31, 2012
Novo Nordisk A/S's Management Discusses Investor and Analyst Meeting at EASD 2012 (Transcript)
Wed, Oct 3, 2012
Novo Nordisk's Management Hosts International Operations Conference Call (Transcript)
Wed, Sep 19, 2012
Novo Nordisk A/S Management Discusses Q2 2012 Results - Earnings Call Transcript
Mon, Aug 13, 2012
Novo Nordisk A/S Management Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Aug 9, 2012
Novo Nordisk CEO Discusses Q3 2010 Results – Earnings Call Transcript
Sun, Oct 31, 2010
Novo Nordisk A/S Q2 2010 Earnings Call Transcript
Mon, Aug 9, 2010
Novo Nordisk A/S Q1 2010 Earnings Conference Call
Fri, Jun 18, 2010
Novo Nordisk A/S Investor presentation on Victoza® launch and International Operation Transcript
Fri, Jun 11, 2010
Novo Nordisk A/S Q4 2009 Earnings Call Transcript
Tue, Feb 2, 2010

Novo Nordisk Unveils New U.S. Headquarters

PR Newswire (Apr 19, 2013)
Europe Markets: Cyprus bank-deposit levy bruises Europe stocks

at MarketWatch.com (Mar 18, 2013)
Europe Markets: Europe stocks drop with China, sequester in focus

at MarketWatch.com (Mar 4, 2013)
Health-care Stocks: Novo Nordisk shares plunge on FDA rejection

at MarketWatch.com (Feb 11, 2013)
Europe Markets: Novo Nordisk leads Europe lower after FDA news

at MarketWatch.com (Feb 11, 2013)
Novo Nordisk Shares Tumble on FDA Letter

at Fox Business (Feb 11, 2013)
Novo Nordisk Promotes Four Members of U.S. Leadership Team to Senior Vice President

PR Newswire (Jan 31, 2013)
Novo Nordisk Named to FORTUNE's "100 Best Companies to Work For" List for Fifth Consecutive Year

PR Newswire (Jan 17, 2013)
Europe Markets: Europe trades sideways with U.S., China in focus

at MarketWatch.com (Jan 11, 2013)
Europe Markets: Europe stocks rebound after U.S. jobs data

at MarketWatch.com (Dec 7, 2012)
Europe Markets: European stocks rise after Greece debt deal

at MarketWatch.com (Nov 27, 2012)
Europe Markets: Europe stocks drop 1.7% on week, Greece weighs

at MarketWatch.com (Nov 9, 2012)
Shares Close Narrowly Higher After US Data

at CNBC.com (Nov 9, 2012)
Health-care Stocks: Express Scripts hammered in wake of comments

at MarketWatch.com (Nov 6, 2012)
Europe Markets: Europe stocks rise with all eyes on U.S. election

at MarketWatch.com (Nov 6, 2012)
Health-care Stocks: Ratings note doesn’t help Abbott in sell-off

at MarketWatch.com (Oct 19, 2012)
Novo Nordisk Gets EU Nod for Long-Lasting Insulin Drug

at Fox Business (Oct 19, 2012)
Europe Markets: Europe stocks rise after Chinese, U.S. data

at MarketWatch.com (Oct 15, 2012)
Europe Markets: Europe stocks wobble as ECB leaves rates unchanged

at MarketWatch.com (Oct 4, 2012)
Europe Markets: Spain bailout speculation lifts European stocks

at MarketWatch.com (Sep 21, 2012)

NVO vs. ETF Alternatives

Company Description

Currently, there's no company description for NVO.

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: Denmark

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 1, 5:24 AM More on Novo Nordisk's (NVO) Q1: Stronger insulin and Victoza sales drive a 28% increase in Q1 profits. Specifically, the company says sales of diabetes treatment Victoza soared 35% during the period, while revenues from modern insulins rose 14%. The company's results shrugged-off a U.S. regulatory setback related to the approval of a new insulin product, Tresiba. NVO also upps its FY13 guidance for revenue growth (now expected to be between 9-11%) and reiterates its outlook for operating profits. Comment! [Healthcare, Earnings]
Wednesday, May 1, 5:04 AM Novo Nordisk (NVO): Q1 EPS of DKK10.98 beats by DKK0.31. Revenue of DKK20B. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, May 1, 12:05 AM Notable earnings before Wednesday’ s open: AB, ADT, AFAM, AFSI, AGN, AH, AMT, ARW, AVA, CCJ, CHK, CLH, CLX, CMCSA, CVH, CVS, DLPH, DVN, ENR, EXAS, EXC,GRMN, GWR, H, HSP, HUM, ICE, IPGP, IQNT, IRM, JRCC, KCG, KFN, MA, MKL, MRK, NVO, PDCE, PKD, POR, PSX, RDC, RDN, SEE, SPW, TLM, TWX, VG, VIAB, VPHM Comment! [Earnings]
Tuesday, April 30, 5:30 PM Notable earnings before Wednesday’ s open: AB, ADT, AFAM, AFSI, AGN, AH, AMT, ARW, AVA, CCJ, CHK, CLH, CLX, CMCSA, CVH, CVS, DLPH, DVN, ENR, EXAS, EXC,GRMN, GWR, H, HSP, HUM, ICE, IPGP, IQNT, IRM, JRCC, KCG, KFN, MA, MKL, MRK, NVO, PDCE, PKD, POR, PSX, RDC, RDN, SEE, SPW, TLM, TWX, VG, VIAB, VPHM Comment! [Earnings]
Wednesday, March 20, 9:46 AM Novo Nordisk (NVO) successfully completes the Phase I trial of its NN1954 insulin tablet for treating diabetes. The aim of the study is to assess the medicine's safety, tolerability, exposure and effect on blood-sugar levels. (PR) Comment! [Healthcare]
Monday, March 18, 9:10 AM Premarket gainers: FU +19%. PRWT +9%. GALE +7%. CLSN +7%.
Losers: AMBO -15%. INCY -12%. FBN -11%. JVA -8%. NBG -6%. ING -6%. NVO -5%. Comment! [On the Move]
Thursday, March 14, 5:48 PM The FDA is reviewing data on a certain class of diabetes drugs which it says might lead to precancerous changes in the pancreas. The drugs may include Eli Lilly's (LLY) Tradjenta, Merck's (MRK) Januvia, Novo Nordisk's (NVO) Victoza, and Bristol-Myers Squibb's (BMY) Byetta. Labels on the drugs already warn of increased potential for pancreatitis, which is the inflamation of the pancreas. The precancerous changes are new, and would affect future labeling. 4 Comments [Healthcare]
Tuesday, February 26, 9:51 AM Merck's (MRK +0.2%) and Bristol-Myers Squibb's (BMY +0.7%) multi-billion dollar diabetes drugs could double the risks of patients developing pancreatitis, which is an inflammation of the pancreas, a study indicates. Merck's Januvia and Bristol-Myers' Byetta increase GLP-1, a hormone that stimulates the pancreas' insulin output. Other drugs that do the same but weren't in study include Bristol's Onglyza and Novo Nordisk's (NVO) Victoza. Comment! [Healthcare]
Monday, February 11, 12:45 PM Midday top 10 gainers: OBT +37%. ZN +22%. MLNK +17%. OESX +14%. MDCI +13%. MCBC +13%. UNXL +11%. XRSC +11%. DMND +11%. IEP +11%.
Midday top 10 losers: NVO -15%. GMXR -14%. DSKX -11%. ESTE -10%. AMBO -10%. CRVP -9%. ALCS -8%. GALT -8%. HEK -8%. BIOL -8%. Comment! [On the Move]
Monday, February 11, 9:15 AM Premarket gainers: CLSN +9%. AUDC +7%.
Losers: NVO -14%. RDN -7%. CZR -7%. HEK -5%.
1 Comment [On the Move]
Monday, February 11, 8:06 AM Sanofi (SNY +3.9%) could be one beneficiaries of the FDA's rejection of two Novo Nordisk (NVO -13.3%) diabetes treatments, as the medicines were seen as a threat to the French company's Lantus, which is the top-selling insulin product in the U.S. Novo hopes to meet with the FDA this week over the decision and its request for more data on the heart risks. Comment! [On the Move, Healthcare]
Monday, February 11, 4:59 AM Novo Nordisk (NVO) shares plunge 11.85% premarket after the FDA unexpectedly rejected the company's Tresiba long-acting insulin and a related product called Ryzodeg. The FDA requested more data from a dedicated cardiovascular outcomes trial, which Novo doesn't expect to be able to provide this year. Tresiba and Ryzodeg are approved in Europe and Japan, and are forecast to generate billions of dollars of sales - assuming U.S. approval.
10 Comments [On the Move, Healthcare, Top Stories]
Thursday, January 31, 4:01 AM Novo Nordisk (NVO): Q4 EPS of DKK10.53 beats by DKK0.77. Q4 EBIT +25% to DKK7.57B. Net profit +23% to DKK5.75B. Sales +16% to DKK20.96B. Sales of diabetes drug was driven by Victoza +29%, modern insulins +20%, NovoSeven +20%. Expects FY13 sales growth to be 8-11%, Operating profit growth to be approx. 10%. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, January 31, 12:05 AM Notable earnings before Thursday’s open: AET, ALKS, AN, APU, AZN, BEAV, BLL, BMS, BX, CAM, CL, CNH, CNX, COCO, CRR, D, DB, DNKN, DOW, EPD, ERIC, EXXI, HAR, HGG, HP, HSH, HSY, IVZ, LQDT, MA, MJN, MO, MTG, MWW, NDAQ, NVO, OXY, PBI, PCAR, PENN, PHM, POT, R, RCL, RGLD, SHW, TE, TEN, TMO, TWC, UA, UGI, UPS, VIAB, WHR, XEL, ZMH Comment! [Earnings]
Wednesday, January 30, 5:30 PM Notable earnings before Thursday’s open: AET, ALKS, AN, APU, AZN, BEAV, BLL, BMS, BX, CAM, CL, CNH, CNX, COCO, CRR, D, DB, DNKN, DOW, EPD, ERIC, EXXI, HAR, HGG, HP, HSH, HSY, IVZ, LQDT, MA, MJN, MO, MTG, MWW, NDAQ, NVO, OXY, PBI, PCAR, PENN, PHM, POT, R, RCL, RGLD, SHW, TE, TEN, TMO, TWC, UA, UGI, UPS, VIAB, WHR, XEL, ZMH Comment! [Earnings]
Tuesday, November 27, 2012, 10:16 AM Novo Nordisk's (NVO -0.2%) Victoza's outperformed Merck's (MRK -0.2%) Januvia and Amylin's (BMY) exenatid BID in patients with type two diabetes. More subjects given Victoza had a blood-sugar level below 7% those who received the rival drugs. (PR) 1 Comment [Healthcare]

Dividend Sheet
$AZN $SJR and $BBL are the highest yielding foreign dividend growth stocks - http://stks.co/pDU6 - 20 stocks with 2.86% Yield - $ACN $NVO
Mon, 3:34 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dividend Sheet
$CYS $KAR and $PNY are tomorrow's best yielding ex-dividend stocks - http://stks.co/p63S - 8 shares with 3.60% average yield $CIB $NVO
Mar 20, 6:05 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Nicholas Ward
$NVO down nearly 5% today, pay close attention if you're interested in picking up shares
Mar 18, 11:07 PM
Reply (2)

• !Report Abuse
View all 2 replies
chopchop0: even cheaper ex-divvy now
Mar 21, 9:57 AM
• !Report Abuse
Nicholas Ward: Yes, I'm watching this decline closely, I really like NVO long term - this looks like a nice buying opportunity is forming.
Mar 21, 9:59 AM
• !Report Abuse
Add a reply...

140 characters

Saibus Research
why healthcare stocks will always be relevant. HC recently been used as a defensive sector http://on.wsj.com/YNM6jy $NVO #healthcare
Mar 18, 6:55 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

chopchop0
$NVO taking a nice dump today.... any news?
Mar 18, 9:12 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
Today's New Downgrades (3/14/13): $ALDW, $CVI, $NVO, $QIHU, $SLCA, $VHC
Mar 15, 9:37 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

1980XLS-2.0
$NVO http://onion.com/13SRiqM
Mar 13, 9:01 AM
Reply (1)

• !Report Abuse
View all 1 replies
Ocean Man: Nice.
Mar 13, 7:46 PM
• !Report Abuse
Add a reply...

140 characters

ltfinger
New Upgrades (3/5/13): $IDCC, $IWD, $IYT, $LRCX, $MELI, $MHK, $NVO, $PNC, $QCOM, $QIHU, $QLD, $RCII, $RLGY, $SBUX, $SGEN, $SIAL, $SSO, $TD
Mar 5, 11:52 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Weekly Stock Watch: $IMSC.PK, $ANTB.OB, $FPMI.OB, $DIS, $MCD, $AZN, $TEV, $GSK, $KERX, $NVO, $AMRN - http://bit.ly/YJduvy
Mar 4, 7:16 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Weekly Stock Watch ... $AMRN, $ANTB.OB, $SPPI, $WMT, $DLTR, $SKS, $ONVO.PK, $NVO, $LOW, $BBY http://bit.ly/cAHZ42
Feb 25, 7:49 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Nicholas Ward
$NVO down nearly 5% today, pay close attention if you're interested in picking up shares
Mar 18, 11:07 PM
Reply (2)

• !Report Abuse
View all 2 replies
chopchop0: even cheaper ex-divvy now
Mar 21, 9:57 AM
• !Report Abuse
Nicholas Ward: Yes, I'm watching this decline closely, I really like NVO long term - this looks like a nice buying opportunity is forming.
Mar 21, 9:59 AM
• !Report Abuse
Add a reply...

140 characters

1980XLS-2.0
$NVO http://onion.com/13SRiqM
Mar 13, 9:01 AM
Reply (1)

• !Report Abuse
View all 1 replies
Ocean Man: Nice.
Mar 13, 7:46 PM
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Novo Nordisk ($NVO) "is testing higher dosages [of its drugs] for use in obesity." Bad news for $ARNA & $VVUS http://bit.ly/VLBRb5
12/17/12
Reply (9)

• !Report Abuse
View all 9 replies
1980XLS-2.0: $WTW Seasonal Play. New year's resolution, after holiday binge.
12/17/12
• !Report Abuse
Chemist357: To take a pill or inject yourself...I think Novo nordisk would have a long way to go. Only purpose extend patent life...
12/17/12
• !Report Abuse
Add a reply...

140 characters

1980XLS-2.0
NVO http://bit.ly/T2zVtu
10/10/12
Reply (1)

• !Report Abuse
View all 1 replies
iadops40: ARNA
10/10/12
• !Report Abuse
Add a reply...

140 characters

Saibus Research
Top 5 investment ideas of the week http://bit.ly/QTc51Q $AAPL $NVO $BIP $CYS $AGNC $NLY $MTGE $S
8/20/12
Reply (2)

• !Report Abuse
View all 2 replies
DaLatin: Like the list,but, i'd add PBI
8/20/12
• !Report Abuse
Saibus Research: DaLatin, thanks for the idea.
8/24/12
• !Report Abuse
Add a reply...

140 characters

1980XLS-2.0
NVO up big again
2/7/12
Reply (1)

• !Report Abuse
View all 1 replies
Rummeljordan: loving it!
2/7/12
• !Report Abuse
Add a reply...

140 characters

1980XLS-2.0
NVO
2/3/12
Reply (1)

• !Report Abuse
View all 1 replies
Husky Financial: i like NVO
2/3/12
• !Report Abuse
Add a reply...

140 characters

1980XLS-2.0
NVO!
2/2/12
Reply (5)

• !Report Abuse
View all 5 replies
labas112: Is there any news on this jump?
2/2/12
• !Report Abuse
Rummeljordan: Yeah, that MCD had good earnings.
2/2/12
• !Report Abuse
Add a reply...

140 characters

0ZJ
Any idea why there's so much volume in NVO today?
12/8/11
Reply (2)

• !Report Abuse
View all 2 replies
Irishmedic: Nope and I am all over this one, being saying this one is a buy for months, love this stock! It is going to get acummulated, why not today!
12/8/11
• !Report Abuse
0ZJ: I look at the chart, it's almost entirely due to a huge (100K) lot moving in-out-in. Started paying close attention due to breakout.
12/8/11
• !Report Abuse
Add a reply...

140 characters

Chines33
Looking to add some Pharma tomorrow on a down move..Long PG PRU APA DD EMC SBUX...ABT SNY CELG GILD NVO on watch.
11/29/11
Reply (1)

• !Report Abuse
View all 1 replies
Chines33: I have just covered my silver short in AGQ for a .50 gain.
11/29/11
• !Report Abuse
Add a reply...

140 characters

1980XLS
Please, somebody tell CNH and NVO they are european and are supposed to be going down, not up.
11/17/11
Reply (3)

• !Report Abuse
View all 3 replies
1980XLS: I've always liked NVO, but was expecting a correction. CNH has fallen hard off $40 again. Don't underestimate what can happen. NSRGY, Sept 1
11/25/11
• !Report Abuse
JGNorman: NVO declined by 30% from their April High to their October low, before rebounding about 13%.
11/25/11
• !Report Abuse
Add a reply...

140 characters

Chines33
No new debt cuts cut releave downward pressure on healthcare that typically outperforms in bear markets long SNY eying ABT NVO BMY
11/21/11
Reply (19)

• !Report Abuse
View all 19 replies
TruffelPig: Actually, about 50% because I have money markets ongoing that I won't touch.
11/21/11
• !Report Abuse
edje: Chines, what is your year end target?
11/21/11
• !Report Abuse
Add a reply...

140 characters

1980XLS
Despite europe, very positive price action in NVO recently. Today is some kind of "Diabetes Day" or something. use caution before chasing
11/14/11
Reply (1)

• !Report Abuse
View all 1 replies
nasalpancho: I am flummoxed as to what is going on -- We should be down over a point
11/14/11
• !Report Abuse
Add a reply...

140 characters

1980XLS
Never thought I would see a large cap, pharma stock like NVO, up 8%+ in a single day.
10/27/11
Reply (6)

• !Report Abuse
View all 6 replies
Chines33: 1980 MT has put in a double since you sent me that message
10/27/11
• !Report Abuse
1980XLS: Yes, that was only weeks ago too. I did well with it, but shoulda stayed in a bit longer. I stuck to my big CMP conviction trade,pd off Tday
10/27/11
• !Report Abuse
Add a reply...

140 characters

Chines33
I am long UN KO PRU TJX EMC BRCM JCI DD ETN ESV APA VIA/B RIO IAU...looking to add to these positions.Watch list to add IBM SLB PCL WY NVO
10/20/11
Reply (10)

• !Report Abuse
View all 10 replies
Hillbilly Stock Star: Stevie said Chinese big shoppers & table rule only to existing space, sounds like going at chop-shops imo. WYNN
10/20/11
• !Report Abuse
Hillbilly Stock Star: Not the 5-star joints, imo WYNN.
10/20/11
• !Report Abuse
Add a reply...

140 characters

NVO Novo Nordisk A/S

NVO

Novo Nordisk A/S